-$1.08 Earnings Per Share Expected for Spark Therapeutics Inc (NASDAQ:ONCE) This Quarter

Wall Street analysts predict that Spark Therapeutics Inc (NASDAQ:ONCE) will post earnings per share of ($1.08) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Spark Therapeutics’ earnings, with estimates ranging from ($1.40) to ($0.64). Spark Therapeutics reported earnings of $2.07 per share in the same quarter last year, which would suggest a negative year over year growth rate of 152.2%. The company is expected to report its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Spark Therapeutics will report full-year earnings of ($4.31) per share for the current year, with EPS estimates ranging from ($5.64) to ($1.69). For the next fiscal year, analysts expect that the firm will post earnings of ($4.25) per share, with EPS estimates ranging from ($5.65) to ($2.15). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($1.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.33). Spark Therapeutics had a negative return on equity of 16.68% and a negative net margin of 124.33%. The firm had revenue of $20.77 million during the quarter, compared to the consensus estimate of $31.20 million.

Several research firms have recently weighed in on ONCE. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Barclays reaffirmed a “sell” rating on shares of Deutsche Bank in a research note on Monday, March 25th. Eighteen research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $78.45.

Shares of Spark Therapeutics stock traded down $0.29 on Tuesday, hitting $96.12. 310,329 shares of the company traded hands, compared to its average volume of 1,182,516. The company has a 50 day moving average of $101.61. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.59 and a current ratio of 5.94. Spark Therapeutics has a 52 week low of $34.53 and a 52 week high of $114.20. The stock has a market cap of $3.72 billion, a P/E ratio of -45.55 and a beta of 2.08.

Hedge funds have recently modified their holdings of the stock. Chicago Capital Management LLC acquired a new stake in Spark Therapeutics in the first quarter worth about $11,481,000. California Public Employees Retirement System increased its stake in shares of Spark Therapeutics by 21.0% in the first quarter. California Public Employees Retirement System now owns 60,382 shares of the biotechnology company’s stock valued at $6,876,000 after buying an additional 10,482 shares during the period. SG Americas Securities LLC increased its stake in shares of Spark Therapeutics by 6,497.2% in the first quarter. SG Americas Securities LLC now owns 317,060 shares of the biotechnology company’s stock valued at $36,107,000 after buying an additional 312,254 shares during the period. Geode Capital Management LLC increased its stake in shares of Spark Therapeutics by 9.9% in the fourth quarter. Geode Capital Management LLC now owns 370,000 shares of the biotechnology company’s stock valued at $14,481,000 after buying an additional 33,414 shares during the period. Finally, Havens Advisors LLC acquired a new stake in shares of Spark Therapeutics in the first quarter valued at about $2,847,000. 86.75% of the stock is currently owned by institutional investors.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Featured Story: How does inflation affect different investments?

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.